GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (FRA:CR5) » Definitions » Return-on-Tangible-Equity

Oculis Holding AG (FRA:CR5) Return-on-Tangible-Equity : -85.65% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Oculis Holding AG Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Oculis Holding AG's annualized net income for the quarter that ended in Mar. 2024 was €-66.65 Mil. Oculis Holding AG's average shareholder tangible equity for the quarter that ended in Mar. 2024 was €77.82 Mil. Therefore, Oculis Holding AG's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was -85.65%.

The historical rank and industry rank for Oculis Holding AG's Return-on-Tangible-Equity or its related term are showing as below:

FRA:CR5' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -67.94   Med: 0   Max: 0
Current: -67.94

FRA:CR5's Return-on-Tangible-Equity is ranked worse than
60.68% of 1297 companies
in the Biotechnology industry
Industry Median: -47.16 vs FRA:CR5: -67.94

Oculis Holding AG Return-on-Tangible-Equity Historical Data

The historical data trend for Oculis Holding AG's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oculis Holding AG Return-on-Tangible-Equity Chart

Oculis Holding AG Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
- - - -

Oculis Holding AG Quarterly Data
Dec20 Jun21 Sep21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -49.06 -70.81 -57.71 -85.65

Competitive Comparison of Oculis Holding AG's Return-on-Tangible-Equity

For the Biotechnology subindustry, Oculis Holding AG's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oculis Holding AG's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oculis Holding AG's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Oculis Holding AG's Return-on-Tangible-Equity falls into.



Oculis Holding AG Return-on-Tangible-Equity Calculation

Oculis Holding AG's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-94.162/( (-111.663+86.442 )/ 2 )
=-94.162/-12.6105
=N/A %

Oculis Holding AG's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-66.648/( (86.442+69.189)/ 2 )
=-66.648/77.8155
=-85.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Oculis Holding AG  (FRA:CR5) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Oculis Holding AG Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Oculis Holding AG's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Oculis Holding AG (FRA:CR5) Business Description

Traded in Other Exchanges
Address
Bahnhofstrasse 7, Zug, CHE, 6300
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Oculis Holding AG (FRA:CR5) Headlines

No Headlines